Epioxa Hd/Epioxa Kit
(Riboflavin 5'-Phosphate)Small molecule
Epioxa Hd/Epioxa Kit is one of 12 small molecule programs targeting Keratoconus. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Keratoconus
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Pred Forte
NovartisPhase 1
Ricrolin+
IIcahn School of Medicine at Mount Sinai
Phase 3
Hypotonic Riboflavin
CCornea and Laser Eye Institute
Phase 3
Neoral
NovartisPreclinical
Riboflavin
CCornea and Laser Eye Institute
Preclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Apr 15, 2016
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA
NDA NDA203324
Oct 17, 2025
EPIOXA HD/EPIOXA KIT
NDA NDA219910
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Riboflavin 5'-Phosphate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- GGlaukos Corporation